This is an English translation of the Swedish original. In case of discrepancies, the Swedish original shall prevail.

Press release | Umeå May 17, 2023

Lipigon announces last patient's last visit in Phase I trial for the treatment of severe hypertriglyceridemia

Lipigon Pharmaceuticals AB ("Lipigon"), a clinical-stage pharmaceutical company focused on developing novel therapeutics for lipid-related diseases, today announced that the last patient had completed the study protocol of its Phase I clinical trial for drug candidate Lipisense. The trial primarily aimed to assess the safety and tolerability of Lipisense in the treatment of severe hypertriglyceridemia.

Lipisense is a drug candidate developed for the treatment of severe hypertriglyceridemia, a condition characterized by significantly elevated blood lipid triglyceride levels.

The phase I clinical trial, which commenced in May 2022, is a randomized, double-blind, placebo-controlled study intended to evaluate the safety and tolerability of Lipisense in single and multiple doses over four-week treatment periods with Lipisense or placebo. As previously communicated, available data suggest good safety and tolerability. Topline results are expected to be announced during summer 2023.

"We are pleased to announce this significant milestone as the last enrolled patient has completed the four-week treatment protocol and follow-up," stated Stefan K. Nilsson, Chief Executive Officer of Lipigon. "Elevated triglyceride levels increase the risk of atherosclerosis, coronary artery disease, and pancreatitis, and there is a high unmet medical need for treatments with improved safety and efficacy. Globally, approximately. 30% of the adult population suffers from hypertriglyceridemia and this number continues to rise annually. Lipisense has been developed to address this growing healthcare crisis."

About Lipisense
Lipisense is an RNA therapeutics drug candidate that prevents the cells from producing the disease-promoting target protein ANGPTL4 in the liver by destroying the protein-coding RNA before the target protein has been formed. Genetic data demonstrate that ANGPTL4 is an independent risk factor for both cardiovascular disease and type 2 diabetes.

For more information, please contact:
Stefan K. Nilsson, CEO, Lipigon



Tvistevägen 48 C, SE-90736 Umeå, Sweden
Tel: +46(0)705781768, info@lipigon.se
Org.nr: 556810-9077
lipigon.se

Email: stefan@lipigon.se
Phone: +46 705 78 17 68

About Lipigon
Lipigon Pharmaceuticals AB is a clinical-stage pharmaceutical company developing drugs with new, unique mechanisms of action (first-in-class) for diseases caused by disorders in the body's handling of fats. The company's operations are based on over 50 years of lipid research at Umeå University, Sweden. Lipigons initial focus is on orphan drugs and niche indications, but in the long term, the company has the possibility to target broader indications, such as diabetes and cardiovascular disease. Lipigons pipeline includes four active projects: the RNA-drug Lipisense for the treatment of hypertriglyceridemia, an RNA drug for the treatment of acute respiratory distress syndrome, a gene therapy treatment for the rare disease lipodystrophy in collaboration with Combigene AB (publ), and a small molecule program for the treatment of dyslipidemia in collaboration with HitGen (Inc). Read more at www.lipigon.se.

The company's share (LPGO) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission.